- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
|Séverine Vilain uses NanoSight's LM10 NTA system in Santen's R&D laboratory in France|
NanoSight reports on how Nanoparticle Tracking Analysis, NTA, is being used at French company, Santen SAS, to use different nanoemulsions for applications in the treatment of the human eye.
Santen is a Japanese pharmaceutical company specializing in the development and manufacturing of ophthalmic products. Santen's products are available all over Europe and the company is the leading manufacturer of ophthalmic products in Northern Europe. Santen SAS, located in France, is the innovation center of Santen Pharmaceuticals. This is where the company incubates high technology projects.
Dr Jean-Sebastien Garrigue, Research and Development Director, leads a research team based in Évry, a region in the southern suburbs of Paris, to develop ophthalmic pharmaceutical products based on innovative drug delivery systems, specifically nanoemulsions. The company applies a technology platform for topical delivery on the ocular surface with Novasorb® cationic nanoemulsions. They also work on a treatment that can be injected inside the eye for the treatment of retinal disease. This is known as Eyeject®, a neutral nanoemulsion.
Describing his work and his use of NTA, Dr Garrigue said "Santen is an innovative company in nanotechnology so we are constantly looking for new and up to date characterization techniques. We needed more accurate equipment to measure the size of our nanoemulsions, to distinguish the different populations and to link the size of the nanoemulsions to their biological efficacy. Also, with NTA we are now able to count nanodroplets in a sample."
Prior to using NTA, the group used the Nanosizer. This is no longer used for research but is kept for routine measurements. Dr Garrigue says more about their use of the NanoSight instrument: "With NTA, we are able to fine-tune our measurement more accurately than with our old equipment. We are able to identify subpopulations that we would not have seen with conventional dynamic light scattering, DLS. Also in case of precipitation of an active ingredient in the form of crystals, we are now able to differentiate crystals from nanodroplets of emulsions."
To find out about the company and to learn more about particle characterization using NanoSight's unique Nanoparticle Tracking Analysis solutions, visit www.nanosight.com/ and register to receive the next issue of NanoTrail, the company's electronic newsletter.
(®Novasorb and Eyeject are registered trademarks of Santen Pharmaceuticals)
NanoSight delivers the world's most versatile and proven multi-parameter nanoparticle analysis in a single instrument.
NanoSight's "Nanoparticle Tracking Analysis" (NTA) detects and visualizes populations of nanoparticles in liquids down to 10 nm, dependent on material, and measures the size of each particle from direct observations of diffusion. Additionally, NanoSight measures concentration and a fluorescence mode differentiates suitably-labelled particles within complex background suspensions. Zeta potential measurements are similarly particle-specific. It is this particle-by-particle methodology that takes NTA beyond traditional light scattering and other ensemble techniques in providing high-resolution particle size distributions and validates data with information-rich video files of the particles moving under Brownian motion.
This simultaneous multiparameter characterization matches the demands of complex biological systems, hence its wide application in development of drug delivery systems, of viral vaccines, and in nanotoxicology. This real-time data gives insight into the kinetics of protein aggregation and other time-dependent phenomena in a qualitative and quantitative manner. NanoSight has a growing role in biodiagnostics, being proven in detection and speciation of nanovesicles (exosomes) and microvesicles.
NanoSight has installed more than 600 systems worldwide with users including BASF, GlaxoSmithKline, Merck, Novartis, Pfizer, Proctor and Gamble, Roche and Unilever together with the most eminent universities and research institutes. NanoSight's technology is validated by 900+ third party papers citing NanoSight results. NanoSight's leadership position in nanoparticle characterization is consolidated further with publication of an ASTM International standard, ASTM E2834, which describes the NTA methodology for detection and analysis of nanoparticles.
For more information, please click here
Amesbury SP4 7RT UK
T +44(0)1980 676060
F +44(0)1980 624703
Talking Science Limited
39 de Bohun Court
Essex CB10 2BA UK
T +44(0)1799 521881
M +44(0)7843 012997
Copyright © NanoSightIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information
Researchers develop new way to manufacture nanofibers May 21st, 2015
Effective Nano-Micelles Designed in Iran to Treat Cancer May 20th, 2015